What is Primobolan Oral?
Primobolan Oral (Methenolone Acetate) is the oral variant of the mild DHT derivative methenolone. Unlike most oral steroids it is not 17a-alkylated but 1-methylated. Even so, it is not gentle on the liver: the Japanese prescribing information of the tablet warns of liver damage and jaundice. On top of that comes markedly lower oral bioavailability. It delivers the same clean, dry gains as the injection, just needing higher doses.
This information is for research and educational purposes only. No medical advice.
Comparison
Methenolone and relatives
Another form of the same compound and related steroids at the same receptor, as described in the TPD lexicon. Tap a card to open its entry.
In a comparison study methenolone bound to the androgen receptor more strongly than testosterone and mesterolone but less strongly than nandrolone. 3
How it works
Like injectable primobolan, the oral form mildly activates the androgen receptor, does not aromatize and causes no estrogen side effects. Due to low oral bioavailability less compound reaches the blood - hence the higher mg figures compared to 17a-alkylated orals.
Where it acts
Where methenolone acted in studies
Tap a point or a card. Colour = target, grey = observed, partly only in single cases.
- Skeletal muscle
Binds to the androgen receptor in muscle more strongly than testosterone (rat and rabbit)3
AR - Blood formation
Response in 11 of 15 people with anaemia from bone marrow failure, on top of ATG5
Observed in trials - Bone
Loss of bone density slowed, a single case6
Observed in trials - Liver
Fatal liver failure in a frail patient, a single case7
Observed in trials - Testes and hormone axis
Anabolic steroids suppress own hormone production, sometimes for months2
Observed in trials
Known targets3
Compound CHEMBL2106880: one described target, Binding, stronger than testosterone (muscle and prostate, rat and rabbit).
- Gene
- AR
- UniProt
- P10275
- ChEMBL
- CHEMBL1871
- Action
- Binding, stronger than testosterone (muscle and prostate, rat and rabbit)
Use and dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
What the research shows
Methenolone has historical clinical use in anemia and muscle wasting. The AAS pharmacology (Kicman 2008, Hartgens & Kuipers 2004) classes it as a mild, non-aromatizing DHT derivative.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
Anaemia from bone marrow failure5
30 people, randomly assigned, all with the immune therapy ATG
Response calculated from the numbers in the abstract, the abstract gives 31% for the group without methenolone. According to the authors the side effects of ATG and androgens were considerable but manageable. An American study found no benefit of the combination.
Haemoglobin in an older man with MDS6
Anaemia from myelodysplastic syndrome and kidney disease
A single patient, together with darbepoetin (stimulates blood formation). According to the authors liver values and PSA stayed normal.
Bone density per year in the same case6
Change before and during treatment
Values from the table in the full text. A single case without a comparison group, the authors cannot prove a causal link.
Research status
Where the research stands
ClinicalTrials.gov lists no trial of its own for methenolone acetate. Listed are an analysis of Japanese claims data with methenolone and a study that names the methenolone enanthate injection among many substances. As of 26 Oct 2026. 12
- Preclinical Structure at the membrane receptor GPR133
- Phase 1 no registered trial
- Phase 2 no registered trial
- Phase 3 no registered trial
- Approval in Japan as a tablet
Show all 2 trials on a timelineHide timeline
NCT06669221 · 1,603 participants, started May 2022, primary endpoint reached Nov 2023. Tests several agents.
Registry entry ↗ · Results not yet in PubMed
NCT07568574 · 60 participants (planned), started Mar 2026, primary endpoint planned May 2028. Tests several agents.
Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026.
Side effects
- Liver: even without 17a alkylation the Japanese prescribing information lists liver damage and jaundice as serious side effects (frequency unknown) and requires regular liver tests with longer use. A case report describes fatal liver failure in a frail 75-year-old (Tsukamoto 1993).
- Androgenic (DHT derivative) - hair loss possible in predisposed individuals.
- HPTA suppression - PCT topic.
- No estrogen side effects.
Storage
Store dry and cool, protected from light. Out of reach of children.